Domain Interdependence in the Biosynthetic Assembly of CFTR
Abstract
The dimerization of their two nucleotide binding domains (NBDs) in a so-called "nucleotide-sandwich" is the hallmark of ATP cassette binding (ABC) proteins and the basis of their catalytic activities. The major disease-causing mutation in the cystic fibrosis transmembrane conductance regulator (CFTR or ABCC7), deletion of Phe508 in NBD1, does not grossly alter the structure of that domain but prevents conformational maturation of the whole CFTR protein, possibly by disrupting the native interaction between NBD1 and NBD2. However, the role of inter-domain interactions in CFTR folding has been brought into question by a recent report that all CFTR domains fold independently. Here we show that in addition to domain folding, correct inter-domain assembly is essential to form a stable unit that satisfies endoplasmic reticulum (ER) quality control. N-terminal domains depend on their more C-terminal neighbors, most essentially the second membrane-spanning domain (MSD2) but significantly, not NBD2. Wild-type C-terminal truncation constructs, completely devoid of NBD2 are transported out of the ER and to the cell surface where they form characteristic CFTR chloride channels with low open probability. The DeltaNBD2 wild-type protein matures and has similar stability as its full-length counterpart. Therefore, the catalytically crucial inter-NBD associations are not required to satisfy ER quality control mechanisms. The DeltaF508 mutation arrests the maturation of DeltaNBD2 just as it does full-length CFTR, indicating that DeltaF508 perturbs other portions of the molecule in addition to NBD2. We find that the mutation prevents formation of a compact MSD1, reflected in its susceptibility to protease digestion. This perturbation of MSD1 may in turn prevent its normal integration with MSD2. The dispensability of NBD2 in the folding of more N-terminal domains stands in contrast to the known hypersensitivity to proteolysis of NBD2 in the DeltaF508 protein.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cooperative F508del-CFTR domain misfolding can be robustly reversed by allosteric pharmacochaperones that synergistically stabilize NBD1 unfolding intermediates and the MSD1 by type III (VX-445) and type I (VX-661) correctors, respectively.
“These observations illustrate that the cooperative F508del-CFTR domain misfolding (10, 11, 51) can be robustly reversed by allosteric pharmacochaperones that synergistically stabilize NBD1 unfolding intermediates and the MSD1 by type III (VX-445) and type I (VX-661) correctors, respectively.”
From Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination (2020) · cites this paper as [51]
Cited by
Sorted by citations
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088 · see citing works
Veit, G., Roldan, A., Hancock, M. A., Da Fonte, D. F., Xu, H., Hussein, M., Frenkiel, S., Matouk, E., Velkov, T., & Lukacs, G. L. (2020) · JCI Insight · doi:10.1172/jci.insight.139983 · Cited by 250 · see citing works
(2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000089 · Cited by 5 · see citing works
- Authors
- Cui, L., Aleksandrov, L., Chang, X.-B., Hou, Y.-X., He, L., Hegedus, T., Gentzsch, M., Aleksandrov, A., Balch, W. E., & Riordan, J. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Scripps Research Institute (US)
- Corresponding author
- Riordan, John R.
- Venue
- Journal of Molecular Biology
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 365
- Issue
- 4
- Pages
- 981-994
- ISSN
- 0022-2836 (ISSN-L)
- OpenAlex
- W2040690917
- Cited by
- 216
- References
- 0
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 13 · 2021: 9 · 2020: 9 · 2019: 5 · 2018: 16 · 2017: 11 · 2016: 12 · 2015: 14 · 2014: 11 · 2013: 11 · 2012: 18
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Molecular Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- CFTR, nucleotide-binding domain, domain-domain interactions, protein folding, ER quality control, F508del mutation, NBD2, protein maturation, protease sensitivity, ABC transporters, cystic fibrosis, chloride channel gating
- MeSH terms
- Adenosine Triphosphate, Amino Acid Sequence, Animals, Epitopes, Cell Line, Glycoside Hydrolases, Cricetinae, Humans, Molecular Sequence Data, Protein Binding, Trypsin, Sequence Homology, Amino Acid, Protein Structure, Tertiary, Cystic Fibrosis Transmembrane Conductance Regulator, Dimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review